Clinical trial
An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects
NCT01437384 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2011
- Completion date
- Not reported
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
idiopathic thrombocytopenic purpura (itp)